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Rapid Communication
Inhibition of Nitric Oxide Synthase Activity Attenuates
Striatal Malonate Lesions in Rats
Abstract: Mitochondrial inhibitors such as malonate are potent
neurotoxins in vivo . Intrastriatal injections of malonate result in
neuronal damage reminiscent of "excitotoxic" lesions produced
by compounds that activate NMDA receptors. Although the
mechanism of cell death produced by malonate is uncertain,
overactivation of NMDAreceptors may be involved ; pretreatment
of animals with NMDA antagonists provides neuroprotection
against malonate lesions . NMDA receptor activation stimulates
the enzyme nitric oxide (NO) Synthase (NOS) . Elevated tissue
levels of NO may generate highly reactive intermediates that
impair mitochondrial function . We hypothesized that NO may be
a mediator of malonate toxicity. We investigated whether in vivo
inhibition of NO production by the NOS inhibitor Nw-nitro-~-argi-
nine (NLA) would attenuate lesions produced by intrastriatal in-
jections of malonate . We found that systemic injections of 3 mg/
kg of NLA significantly reduced the extent of histologic damage
elicited by intrastriatal injections of 1 .5 ~mol of malonate in adult
rats. Key Words: Malonate lesions-Rat striatum-Nitric ox-
ide-Nitric oxide Synthase inhibition-NW-Nitro-~-arginine.
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Malonate reversibly inhibits the enzyme succinate dehy-
drogenase in both the tricarboxylic acid cycle and respiratory
chain (Webb, 1966) . It may also block mitochondrial anion
transport (Bryla, 1980) . Direct intracerebral injections of
micromole quantities ofmalonate elicit focal necrotic lesions
in adult rats . It has been speculated that lesions produced by
malonate in the CNS occur via indirect overactivation of the
N-methyl-D-aspartate ( NMDA ) glutamate receptor subtype
(Henshaw et al ., 1994) . Specifically, it has been postulated
that the reduction of neuronal energy stores results in neu-
ronal depolarization, which relieves the Mg t+ gating of the
NMDA-associated channel, which ultimately allows ambient
levels of glutamate to activate the receptor and cause a mas-
sive influx of Caz+ (Beal, 1992). Support for this hypothesis
comes from in vivo studies in which malonate-induced le-
sions were attenuated by pretreatment with the noncompeti-
tive NMDA inhibitor MK-801 (Beal et al ., 1993 ; Greene et
al., 1993) .
Nitric oxide (NO) is an endogenous CNS messenger pro-
duced by the enzyme NO Synthase (NOS) (Bredt and Sny-
der, 1990) . Compounds, such as nitroprusside, that generate
NO are neurotoxic when injected into the brain (Loiacono
and Beart, 1992) . Recent data suggest that NO is an im-
portant mediator of injury resulting from NMDA receptor
overactivation (Dawson and Snyder, 1994) . Inhibition of
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NOS is neuroprotective in several models of cerebral isch-
emia and in some paradigms against excitatory amino acid
toxicity (for discussion, see Dawson and Snyder, 1994) ;
altered regulation of vascular NOS has confounded analysis
of neuroprotection by NOS inhibition . The mechánism of
NO toxicity is uncertain. NO reacts with superoxide free
radicals to form highly reactive intermediates (Beckman et
al ., 1990), some of which may diminish mitochondrial oxi-
dative phosphorylation (Bolaíïos et al ., 1994) ; impaired mi-
tochondrial function results in potentially lethal decreases in
energy production . Because NMDA toxicity may, in part,
be mediated by NO, we hypothesized that NO might also be
a mediator of malonate toxicity . Therefore, we investigated
whether in vivo inhibition of NO production by the NOS
inhibitor N"-nitro-L-arginine (NLA) would attenuate malo-
nate toxícíty .
MATERIALS AND METHODS
Male Sprague-Dawley rats were used in all experiments .
All animal use procedures were in accordance with the NIH
Guidefor the Care and Use ofLaboratory Animals and were
approved by the University of Michigan Committee on the
Use and Care of Animals. Malonate and NLA were obtained
from Sigma (St. Louis, MO, U.S .A .), and Nw-nitro-D-argi-
nine (NDA) was from Calbiochem (San Diego, CA,
U.S.A .) .
In the initial experiment, 8-week-old animals (n = 24 ;
weighing 190-210 g) were used . Six of them were injected
intraperitoneally with 1 .0 ml/kg of 0.1 M phosphate buffer
(pH 7.4), and six received 3 mg/kg of NLA, i.p. One hour
later, animals were anesthetized with ether and placed in a
small animal stereotaxic apparatus with the incisor bar at
-2.4 mm. Using a 30-gauge Hamilton syringe, each animal
received an injection of 1.5 /Cmol of malonate (dissolved in
phosphate buffer, pH 7 .4) into the right striatum over 90 s.
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The coordinates for the striatum were AP +0.8 mm, ML
2.5, relative to bregma, and DV -5.0 from the surface of
the brain. Following injections, the needle was left in place
for 1 min before the scalp was stapled shut and the animals
were returned to their cages. Rectal temperatures in the con-
trol and pretreatment groups were obtained 1 h before, dur-
ing, and 10 and 60 min after malonate injections . Subse-
quently, the experiment was replicated in 12 additional
8-week-old animals. In two additional experiments, the iden-
tical protocol was performed using 12-week-old rats (n = 24 ;
weighing 320-355 g). In each experiment, freshly prepared
solutions, maintained on ice, were used .
In a third experiment, we evaluated the stereospecificity
of NLA by evaluating the neuroprotective properties of its
inactive isoform, NDA, in 12-week-old rats (n = 12 ;
weighing 320-358 g) . In this study, six rats were pretreated
with 3 mg/kg of NDA and six with 1.0 ml/kg of 0.1 M
phosphate buffer (pH 7.4), i.p ., 1 h before receiving a striatal
injection of 1 .5 pmol of malonate .
Animals were killed 7 days later by decapitation, and the
brains were rapidly removed and frozen on powdered dry
ice . The brains were stored at -70°C until sectioning . For
histological analysis, 20-/cm-thick frozen coronal sections
obtained at 80-pm intervals were thaw-mounted on gelatin-
coated slides. Following a 2-day exposure to paraformalde-
hyde vapor at room temperature, sections were stained for
Nissl substance using cresyl violet . In samples from the first
group of animals, adjacent 20-pm sections were obtained
and processed for cytochrome oxidase according to the
method of Wong-Riley et al . (1978) . Using computer-based
image analysis (Imaging Research Inc., St . Catherines, On-
tario, Canada), severity of injury was assessed by comparing
the averaged regional cross-sectional area of the lesion in
the 10 cresyl violet-stained sections anterior and posterior to
the center of the injection site . Cytochrome oxidase-stained
sections were used as a complementary method to verify
extent of lesions but were not quantified . Histological com-
parisons were made using Mann-Whitney nonparametric
analysis . The results are reported as mean ± SEM values .
RESULTS
All of the control animals in both age groups emerged
from anesthesia within ---30 min. The majority of animals
pretreated with NLA exhibited 5-10 min of clonic axial
extension during this period before resuming normal activity ;
none of the control or NDA-pretreated animals displayed
this behavior. There was no difference in core temperature
between the control and pretreatment groups tested at any
time before, during, or up to 1 h following surgery (data not
shown) . In the initial experiment, one pretreatment animal
was excluded from data analysis owing to misplacement of
the needle tip . Among the 12-week-old animals, one control
and one NLA-treated animals died following surgery.
In the 12 8-week-old control rats that were injected with
malonate, marked variability in the severity of resultant le-
sions was noted in both cresyl violet- and cytochrome oxi-
dase-stained material . The average lesion area was 2.17
± 0.49 mm2 . Seven of 12 animals developed lesions with a
mean area of ~1 mm2 (range, 1 .01-5.5 mm2) ; based on
comparison with the mean area of the contralateral striatum
over the same anterior-posterior distance, the lesions re-
sulted in a 10-50% reduction in average area . In the re-
maining five animals, lesions were much less pronounced,
and the cross-sectional areas ranged between 0.45 and 0.93
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mm2 (4.5-9.3% damage) . Microscopic analysis of cresyl
violet-stained sections of the more severe malonate-induced
lesions demonstrated a necrotic core surrounded by marked
neuronal loss and glial proliferation (Fig . lA) . Sections pro-
cessed for cytochrome oxidase activity revealed focal reduc-
tion in reaction product coinciding with loss of Nissl stain
( Fig. 1C ) . The smaller lesions were characterized by cell
loss and gliosis extending just beyond the needle tract .
In 10 of 11 8-week-old animals pretreated with NLA,
the malonate-induced lesions were more homogeneous and
consisted of a small circumscribed area of cell loss and
gliosis immediately surrounding the needle track; there was
accompanying preservation of cytochrome oxidase activity
(Fig . 1B and D) . The mean ± SEM lesion area, based on
average values from these 11 animals, was 0.71 ± 0.22
mm2 (13% damage) . Comparison of the average lesion areas
between the two groups demonstrated a significant difference
(p < 0.004 ) ; mean lesion areas in NLA-treated animals
were reduced by 67% ( Fig. 2) .
The marked variability of lesion size observed in the con-
trol group of 8-week-old animals prompted us to perform
the second group of experiments in older (12-week-old) rats,
which were likely to be more susceptible to mitochondrial
toxins (Beal et al ., 1993) . The lesions in the 12-week-old
control animals were much more homogeneous. In this
group, six of 11 animals had lesions that involved almost
the entire striatum and, in one case, extended beyond it ;
these lesions were approximately twice as large as the most
severe lesions in the younger rats and ranged from 7.6 to
9.8 mm2 (83-107% damage compared with the contralateral
striatum) . In the remaining five controls, lesions were similar
in magnitude to the largest lesions in the young animals and
ranged from 3.6 to 6.9 mm2 (39-75% damage) . The average
area of the lesions in these 11 animals was 7.15 ± 0.54
mm2 , significantly larger (p < 0.0001) than the lesions in
the 8-week-old animals. In 10 of 11 of the NLA-treated
animals, the average lesion area was 5 .14 -!- 0.43 mm2
(range, 2.2-7 .4 mm2 ) ; one rat had no discernible lesion and
was excluded from the analysis . Compared with the intact
contralateral striatum, this represents 24-80% striatal dam-
age. In these NLA-treated animals, the average area of the
malonate-induced striatal lesion was reduced 30% compared
with the control (p < 0.01 ; Fig. 2) .
In the third experiment to evaluate the effects of NDA in
12-week-old rats, striatal malonate lesions in the saline con-
trol group were homogeneous ; mean lesion areas did not
differ from values in the previous group of 12-week-old
control animals. The average lesion area was 8.26 ± 2.26
mm2 (range, 6.3-10.5 mm2 ; 57-95% damage) . In the six
animals that were pretreated with NDA, the average lesion
area was 8.19 ± 1.03 mm2 (range, 6.6-9 .4 mm2 ; 63-90%




We assessed the neuroprotective effects of the NOS inhib-
itor NLA on striatal lesions induced by the mitochondrial
inhibitor malonate. Because lesions produced by malonate
may be mediated, in part, by NMDA receptor activation
(Henshaw et al ., 1994) and because NMDA receptor activa-
tion results in the production of NO (Garthwaite et al .,
1989), we speculated that impairment of NO production
would attenuate malonate lesions . Although several studies
have shown that NOS inhibitors are neuroprotective against
J. Neurochem ., Vol. 64, No. 5, 1995
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NMDA receptor-mediated neurotoxicity and hypoxia/isch-
emia, these findings have been challenged by other reports
that demonstrated either no protection or enhancement of
lesions (see Dawson and Snyder, 1994) . Several recent
dose-response studies using NLA in different models of
hypoxia/ischemia have indicated that low doses of NLA
provide maximal neuroprotection (Nagafuji et al ., 1993 ; Car-
reau et al ., 1994) ; thus, we selected a pretreatment dose of
3 mg/kg. Our data demonstrate that inhibition of NOS with a
low dose of NLA confers significant neuroprotection against
malonate-induced lesions in a stereospecific manner . Our
findings are supported by a recent preliminary report demon-
FIG. 2. Summary of the results of three independent experi-
ments in which all of the animals received intrastriatal injections
of 1 .5 ~mol of malonate . A and B: Comparison of the mean
areas of lesions in control and NLA-pretreated animals that were
8 (A) or 12 (B) weeks old when lesioned . In A, 12 control and
11 NLA-treated animals were compared ; in B, 11 control and
10 NLA-treated animals were compared . C: Comparison of the
outcome in 12-week-old animals (n = 6 per group) that were
treated with saline or the inactive stereoisomer NDA (3 mg/kg) .
All animals were killed 1 week after lesioning . Lesion areas were
measured in 20 coronal brain sections by computer-assisted
image analysis (see Materials and Methods) . 'p < 0.004,
"p
< 0.01 by Mann-Whitney test . Data are mean ± SEM (bars)
values .
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FIG. 1. Cresyl violet-stained coro-
nal brain sections at the level of the
striatum demonstrate the histo-
pathological features of malonate
lesions in 8-week-old (A) control
and (B) NLA (3 mg/kg, i .p .)-pre-
treated animals. A represents one
of the larger malonate lesions, and
B illustrates a lesion in which the
degree of neuroprotection was
greater than average. Each animal
was injected with 1 .5 ~mol of malo-
nate and was killed 1 week later .
C and D: Corresponding adjacent
sections in which cytochrome oxi-
dase activity was histochemically
assayed demonstrate the extent of
loss of activity closely parallels his-
topathological extent of tissue de-
struction .
strafing that the NOS inhibitor 7-nitroindazole also confers
neuroprotection against mitochondrial toxin-induced lesions
(Shulz et al ., 1994) .
Our data also demonstrated a marked variation in neuronal
susceptibility to malonate toxicity in the younger adult rats .
The extent of tissue damage determined in Cresyl violet-
stained brain sections was confirmed using alternate sections
stained for cytochrome oxidase, which demonstrated identi-
cal lesion boundaries . Beal et al . (1993 ) demonstrated a
direct relationship between age and severity of lesions in
malonate-lesioned rats ; they found no reduction in neuro-
chemical markers in the striatum of 1-month-old rats injected
with 2.0 /Cmol of malonate and a maximal reduction at 4
months . In 8-week-old young adults, the marked intergroup
variability in histopathological outcome after intracerebral
malonate injections was unexpected and has not been pre-
viously reported . The reason for this variability in lesion size
within the group of younger animals is uncertain . These
findings demonstrate that, in future studies of mitochondrial
toxicity, it will be critical to consider age effects .
Our results suggest that NO is a mediator of malonate
toxicity . The mechanisms of NO-mediated toxicity are com-
plex. NO induces the formation of cyclic GMP (Knowles et
al ., 1989) and peroxynitrite (Beckman et al., 1990), each
of which can have deleterious effects on cell function ; in-
creases in NO content also cause the ADP ribosylation of
some proteins (Brune and Lapetina, 1989) and inhibition of
mitochondrial function in astrocytes (Bolaíïos et al ., 1994) .
Although these individual processes were not evaluated in
this study, it is likely that more than one contribute to cell
death. Additional complexity in determining the mechanism
by which NLA attenuated toxicity lies in NOS itself. There
are at least three forms of NOS: neuronal and endothelial
(both of which are constitutive) and astrocytic (which is
inducible) . Because NLA is not a specific inhibitor of any
single NOS isoform, it is possible that blockade of NO pro-
duction by any one or all of the different enzymes contrib-
uted to the neuroprotection we observed . Availability of iso-
zyme-specific NOS inhibitors will facilitate identifying the
cellular and molecular sources of NO in malonate-lesioned
brain.
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